### Edgar Filing: Rombotis Spiro George - Form 4

Form 4	C									
January 07, 2019	)									
FORM 4	UNITED	STATES	SECU	RITIES A	AND EX	CHANGE	COMMISSIO	т	PPROVAL	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					N OMB Number:	3235-0287				
Check this box if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securitie					ties Excha	Estimated average burden hours per response				
obligations may continue. <i>See</i> Instruction 1(b).	n			•	•	npany Act ny Act of 1	of 1935 or Section 940	on		
(Print or Type Respo	onses)									
1. Name and Address of Reporting Person <u>*</u> Rombotis Spiro George			2. Issuer Name <b>and</b> Ticker or Trading Symbol Cyclacel Pharmaceuticals, Inc.			5. Relationship of Reporting Person(s) to Issuer				
			[CYCC]				(Check all applicable)			
(Month.			(Month/	. Date of Earliest Transaction Month/Day/Year)			X Director 10% Owner X Officer (give title Other (specify below) below)			
1500	DRIVE, SU		01/03/2	2019			Pre	esident and CEC	)	
			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
BERKELEY HI	EIGHTS, NJ	07922					Person	More than One K	epotting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	ansaction Date nth/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report of	n a separate line	for each cl	ass of sec	urities benef	Perso inforn requir	ns who rest nation cont red to responses a current	or indirectly. pond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)										

#### Edgar Filing: Rombotis Spiro George - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) o Disposed of (D (Instr. 3, 4, and 5)	)	/Year)	(Instr. 3 and	4)
				Code V	(A) (D	) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option	\$ 0.71	01/04/2019		А	508,198	<u>(1)</u>	01/04/2029	Common Stock	508,198
Option	\$ 1.74	01/03/2019		А	15,625	(3)	12/29/2027	Common Stock	15,625
Option	\$ 1.56	01/03/2019		А	14,375	(4)	02/22/2028	Common Stock	14,375

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Rombotis Spiro George 200 CONNELL DRIVE, SUITE 1500 BERKELEY HEIGHTS, NJ 07922	Х		President and CEO		

# Signatures

/s/ Spiro Rombotis	01/07/2019		
<u>**</u> Signature of Reporting Person	Date		

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
- (2) These securities were granted as part of the Issuer's annual compensation review to executive officers.
- On December 29, 2017, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest (3) according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019,
- resulting in the vesting of the option as to 15,625 shares.
- On February 22, 2018, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest
   (4) according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 14,375 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.